MACK - メリマック・ファ―マシュ―ティカルズ （Merrimack Pharmaceuticals Inc.） メリマック・ファ―マシュ―ティカルズMACKのチャート
MACKの企業情報
| symbol | MACK |
|---|---|
| 会社名 | Merrimack Pharmaceuticals Inc （メリマック・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 メリマック・ファーマスーティカルズ(Merrimack Pharmaceuticals Inc.)は臨床段階の生物製薬会社である。同社はバイオマーカーで定義された癌を標的とすることにより、癌の新規治療法の設計に従事する。同社の臨床プログラムにはMM-121(セリバンスマブ)、MM-141（イソチラタブ）およびMM-310が含まれる。MM-121はErbB3（HER3）受容体と標的ヘレグリン陽性癌に特異的に結合する完全ヒトモノクローナル抗体である。MM-141はインスリン様増殖因子1またはIGF-1受容体およびErbB3（HER3）細胞表面受容体を含む受容体複合体を標的化することによって腫瘍生存シグナルを遮断するように設計された完全ヒト4価二重特異性抗体である。MM-310は、エフリンレセプターA2またはEphA2レセプターを標的とする抗体指向性ナノ治療薬であり、強力な化学療法ドセタキセルの新規プロドラッグを含む。 メリマック・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。癌治療に焦点を当てコンパニオン診断による治療薬の開発、商品化を手掛ける。臨床開発における製品候補MM-398、MM-121、MM-111、MM-302、MM-151、MM-141を扱う。またネットワ―ク生物学の観点から開発研究対象の選定、化合物の設計・開発、臨床試験などを行う。 Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive up to $450.0 million in contingent milestone payments related to its sale of ONIVYDE® to Ipsen S.A. in April 2017. These milestone payments would be payable by Ipsen upon approval by the U.S. Food and Drug Administration ('FDA') of ONIVYDE® for certain additional clinical indications. ONIVYDE® is already approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. This existing approval is unrelated to any future potential milestone payments. Merrimack's agreement with Ipsen does not require Ipsen to provide Merrimack with any information on the progress of ONIVYDE® clinical trials that is not publicly available. Merrimack is also entitled to receive up to $54.5 million in contingent milestone payments related to its sale of anti-HER3 programs to Elevation Oncology (formerly 14ner Oncology, Inc.) in July 2019. The Company is seeking potential acquirers for its remaining preclinical assets. |
| 本社所在地 | One Kendall Square Suite B7201 Cambridge MA 02139 USA |
| 代表者氏名 | Gary L. Crocker ゲイリー・L・クロッカー |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 617-441-1000 |
| 設立年月日 | 1993年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2012年 |
| 従業員数 | 294人 |
| url | www.merrimack.com |
| nasdaq_url | https://www.nasdaq.com/symbol/mack |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -63.12400 |
| 終値（lastsale） | 5.04 |
| 時価総額（marketcap） | 67247631.36 |
| 時価総額 | 時価総額（百万ドル） 53.50456 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -6.49944 |
| 当期純利益 | 当期純利益（百万ドル） -32.83400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Merrimack Pharmaceuticals Inc revenues was not reported. Net loss before extraordinary items decreased 38% to $35.6M. Lower net loss reflects Interest expense decrease from $28.7M (expense) to $0K Research and Development Expense decrease of 27% to $26.2M (expense) General and administrative decrease of 58% to $6.9M (expense). |
MACKのテクニカル分析
MACKのニュース
Merrimack Pharmaceuticals GAAP EPS of $0.02 2023/05/04 21:47:44 Seeking Alpha
Merrimack Pharmaceuticals press release (MACK): Q1 GAAP EPS of $0.02.Merrimack reported a gain on the sale of assets for the first quarter ended March 31, 2023, of $139…
Merrimack Pharmaceuticals GAAP EPS of -$0.11 2023/03/09 21:58:50 Seeking Alpha
Merrimack Pharmaceuticals press release (MACK): FY GAAP EPS of -$0.11.As of December 31, 2022, Merrimack had cash and cash equivalents of $19.4 million, compared to $14.2 million as…
Merrimack Reports Full Year 2022 Financial Results 2023/03/09 21:40:00 Merrimack Pharmaceuticals
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 9, 2023-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, 2022 . “We are encouraged by the results of the NAPOLI 3 trial as reported by Ipsen
Current Volume Sizzlers: GeoVax Labs, Inc. (NASDAQ:GOVX -13.51%), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK -0.44%) 2023/01/26 17:06:10 Stock Equity
GOVX has seen its SMA50 which is now 34.08%. In looking the SMA 200 we see that the stock has seen a -16.11%. MACK has seen its SMA50 which is … The post Current Volume Sizzlers: GeoVax Labs, Inc. (NASDAQ:GOVX -13.51%), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK -0.44%) appeared first on Stocks Equity .
Merrimack Still Has Significant Arbitrage Potential (NASDAQ:MACK) 2023/01/04 15:33:10 Seeking Alpha
In Dec. 2022, Merrimack got positive clinical results for its Phase III clinical trial of Onivyde in first line pancreatic cancer. See why we remain bullish on MACK stock.
Merrimack Pharmaceuticals Stock: Out For Now (MACK) 2022/08/08 20:16:30 Seeking Alpha
Merrimack''s partner Ipsen had a recent failure of the applications of its drug ONIVYDE. Read more to find out what this means for MACK stock.
Merrimack Pharmaceuticals GAAP EPS of -$0.04 (NASDAQ:MACK) 2022/08/04 21:12:28 Seeking Alpha
Merrimack Pharmaceuticals press release (MACK): Q2 GAAP EPS of -$0.04.As of June 30, 2022, Merrimack had cash and cash equivalents of $13.4 million, compared to $14.2 million as…
Merrimack Pharma-Ipsen''s Cancer Drug Fails In Overall Survival Measure 2022/08/03 15:49:40 Benzinga
Merrimack Pharmaceuticals Inc''s (NASDAQ: MACK ) partner announced that Ipsen SA (OTC: IPSEY ) reported a primary analysis of the results of the Phase 3 trial of Onivyde (irinotecan liposomal injection)for second-line small cell lung cancer (SCLC). The study did not meet the primary endpoint of overall survival in patients treated with Onivyde … Full story available on Benzinga.com
Merrimack: Ipsen''s Phase 3 Trial Of Onivyde Fails To Meet Primary Endpoint 2022/08/03 13:14:32 Nasdaq
(RTTNews) - Merrimack Pharmaceuticals, Inc. (MACK) said Ipsen has reported its primary analysis of the results of phase 3 trial of Onivyde as a treatment of second line small cell lung cancer. The primary endpoint OS was not met in patients treated with Onivyde versus topotecan.
Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer 2022/08/03 12:30:00 Merrimack Pharmaceuticals
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 3, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] announced that Ipsen, SA (“Ipsen”) has issued a press release today reporting its primary analysis of the results of its Phase 3 trial of Onivyde® (irinotecan liposomal
Merrimack Pharmaceuticals GAAP EPS of -$0.01 2022/05/05 20:49:44 Seeking Alpha
Merrimack Pharmaceuticals press release (MACK): Q1 GAAP EPS of -$0.01.“During the first quarter of 2022 we continued to see reductions in our operating expenses and were able to close…
Merrimack Reports First Quarter 2022 Financial Results 2022/05/05 20:30:00 Merrimack Pharmaceuticals
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 5, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2022 financial results for the period ended March 31, 2022 . “During the first quarter of 2022 we continued to see reductions in our
Merrimack Pharmaceuticals reports FY results (NASDAQ:MACK) 2022/03/09 22:17:18 Seeking Alpha
Merrimack Pharmaceuticals press release (MACK): FY GAAP EPS of -$0.18.As of December 31, 2021, Merrimack had cash and cash equivalents and investments of $14.2 million, compared to…
Merrimack Reports Full Year 2021 Financial Results 2022/03/09 21:30:00 Merrimack Pharmaceuticals
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 9, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2021 financial results for the period ended December 31, 2021 . “During 2021 we have continued to reduce our operating expenses and remain